| __timestamp | BioMarin Pharmaceutical Inc. | TG Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 24518692 |
| Thursday, January 1, 2015 | 402271000 | 19886580 |
| Friday, January 1, 2016 | 476593000 | 12631689 |
| Sunday, January 1, 2017 | 554336000 | 21977998 |
| Monday, January 1, 2018 | 604353000 | 20759000 |
| Tuesday, January 1, 2019 | 680924000 | 20838000 |
| Wednesday, January 1, 2020 | 737669000 | 121812000 |
| Friday, January 1, 2021 | 759375000 | 152137000 |
| Saturday, January 1, 2022 | 854009000 | 83231000 |
| Sunday, January 1, 2023 | 937300000 | 122706000 |
In pursuit of knowledge
In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. Over the past decade, BioMarin Pharmaceutical Inc. and TG Therapeutics, Inc. have shown distinct approaches in managing their Selling, General, and Administrative (SG&A) expenses. BioMarin's SG&A expenses have surged by over 200% from 2014 to 2023, reflecting its aggressive expansion and investment in operational infrastructure. In contrast, TG Therapeutics, while experiencing a significant increase in SG&A expenses, particularly between 2020 and 2021, has maintained a more conservative growth trajectory, with expenses peaking at 152 million in 2021. This divergence highlights BioMarin's robust market positioning and TG Therapeutics' strategic focus on cost management. As the biotech sector continues to evolve, these financial insights offer a glimpse into the strategic priorities shaping the future of these industry players.
SG&A Efficiency Analysis: Comparing Novartis AG and TG Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Neurocrine Biosciences, Inc. and TG Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: Insmed Incorporated vs BioMarin Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Insmed Incorporated and TG Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Ascendis Pharma A/S
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Xencor, Inc. Trends and Insights
Comparing SG&A Expenses: Ascendis Pharma A/S vs TG Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Pharming Group N.V. vs TG Therapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Supernus Pharmaceuticals, Inc.
TG Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends